Patti L Arndt

Learn More
Sixty-three postlinguistically deaf adults from four English-speaking countries participated in a 17-week field study of performance with a new speech coding strategy, Spectral Peak (SPEAK), and the most widely used strategy, Multipeak (MPEAK), both of which are implemented on wearable speech processors of the Nucleus 22 Channel Cochlear Implant System;(More)
A new device incorporating a cochlear implant speech processor and a speech-processing hearing aid for the unimplanted ear has been designed and tested with four severely hearing-impaired patients. The aim of the device is to provide a more acceptable and effective combination of electrical and acoustic signals to the two ears. When used monaurally, and(More)
OBJECTIVE The purpose of this article is to present psychophysical data for 40 Nucleus 24 Contour adult patients with 1 mo of device experience and speech perception results for a group of 56 adult patients with 3 mo experience using the Nucleus 24 Contour cochlear implant system. Postoperative hearing thresholds (i.e., under headphones) in the implanted(More)
Results from 80 pediatric subjects with 12 months of experience wearing the Nucleus multichannel cochlear implant are presented. The data suggest that children demonstrate statistically and clinically significant benefit across a broad spectrum of abilities with the implant. Significant postoperative improvement was demonstrated by 66 percent (51 of 77), 63(More)
OBJECTIVE The Nucleus 24 Advanced Encoder Conversion Study was designed to determine the safety and effectiveness of the advanced combination encoder (ACE) and continuous interleaved sampling (CIS) speech coding strategies compared with that of the spectral peak (SPEAK) strategy in a large sample of postlinguistically deaf adults. Data from this study were(More)
The Nucleus 24 Contour is a new cochlear implant that has recently undergone clinical trials in adults and children. The Contour uses the same electronics as the previous-generation Nucleus 24 (CI24M) but incorporates a downsized receiver-stimulator and a perimodiolar electrode array. The indications for use were expanded to include children as young as 12(More)
Since 1994, a US Food and Drug Administration clinical trial evaluated the multichannel auditory brainstem implant (ABI) on 92 subjects with neurofibromatosis type 2 (NF2). The trial has shown that 85 per cent of patients receive auditory sensations. A small number of patients demonstrate a clinically significant degree of open-set sentence recognition in(More)
  • 1